157 ), and inhibition of PI3K/Akt phosphorylation. These results strongly indicate that CE-WIB801C and cordycepin may have preventive or therapeutic potential for platelet aggregation-mediated diseases, such as thrombosis, myocardial infarction, atherosclerosis, and ischemic cerebrovascular disease. 
INTRODUCTION
Platelet aggregation is caused by "inside-out signaling" and "outside-in signaling", which is absolutely essential for the formation of a hemostatic plug when normal blood vessels are injured. However, platelet aggregation can also cause circulatory disorders, such as thrombosis, atherosclerosis, and myocardial infarction (Schwartz et al., 1990) .
Various agonists (i.e. collagen, thrombin, ADP) induce "in side-out signaling" to bind fibrinogen to glycoprotein IIb/ IIIa (aIIb/b3), platelet membrane integrin, then subsequently cause "outside-in signaling" by binding fibrinogen to aIIb/b3 (van Willigen and Akkerman, 1991; Payrastre et al., 2000; Phillips et al., 2001) . Vasodilator-stimulated phosphoprotein (VASP) phosphorylation inhibits VASP affinity for contractile protein filamentous actin, and fibrinogen binding to aIIb/b3 to inhibit the final common pathway for platelet aggregation (Laurent et al., 1999; Sudo et al., 2003) . aIIb/b3 activation is also stimulated by phosphatidylinositol 3-kinase (PI3K)/Akt phosphorylation (Morello et al., 2009) . In special, the interaction between aIIb/b3 and plasma fibrinogen is known to involve in [Ca 2+ ]i mobilization, tyrosine phosphorylation of Src and Syk, activation of phosphatidylinositol 4,5-bisphosphate hydrolysis by phospholipase C-γ 2 phosphorylation, cytoskeleton reorganization and granule secretion (Clutton et al., 2001; Jennings, 2009) . Therefore, the stimulation of VASP phosphorylation, and the inhibition of PI3K/Akt phosphorylation are very useful for eva luating the antiplatelet effect of substances or compounds. For instance, a major catechin analogue, (-)-epigallocatechin-3-gallate from green tea, is known to produce cAMP via adenylate cyclase activation and subsequently phosphorylates VASP (Ser 157 ) through cAMP-dependent protein kinase
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In previous reports (Cho et al., 2006 (Cho et al., , 2007a (Cho et al., , 2007b , we suggested that cordycepin (3'-deoxyadenosine, Fig. 1 ) inhibits [Ca 2+ ]i mobilization in collagen-, TXA2 analogue U46619-, and tu mor promoter thapsigargin-activated human platelets. In add ition, cordycepin strongly inhibited the phosphorylation of Ca 2+ -dependent proteins (myosin light chain and pleckstrin) by suppressing collagen-, and U46619-elevated [Ca 2+ ]i mobilization (Cho et al., 2006; 2007a) . In recent, we prepared cordycepin-enriched WIB801C (Compound from 2008 First Project of Bioteam, Whanin Pharm. Co., Ltd., Suwon, Korea), a n-butanol extract from Cordyceps militaris-hypha (Lee et al., 2014b) , and reported that cordycepin-enriched (CE) WIB801C has an antiplatelet effect by inhibiting collagen-induced [Ca 2+ ]i mobilization via cAMP-dependent phosphorylation of inositol 1, 4, 5-trisphosphate receptor (IP3R) in human platelet (Lee et al., 2014b) . In this study, we investigated the novel effects of CE-WIB801C on the phosphorylation of VASP and dephosphorylation of PI3K and Akt affecting on fibrinogen binding to aIIb/b3.
MATERIALS AND METHODS

Materials
Collagen was purchased from Chrono-Log Co. (Havertown, PA., USA). ATP assay kit was purchased from Biomedical Research Service Center (Buffalo, NY., USA). Cordycepin, A-kinase inhibitor Rp-8-Br-cAMPS, cGMP-dependent protein kinase (G-kinase) inhibitor Rp-8-Br-cGMPS, A-kinase activator pCPT-cAMP, and G-kinase activator 8-Br-cGMP were ob tained from Sigma Chemical Corporation (St. Louis, MO., USA). Serotonin ELISA kit was purchased from Labor Diagno stika Nord GmbH & CO. (Nordhorn, Germany). Anti-VASP, anti-phosphor-VASP (Ser 157 ), anti-phosphor-VASP (Ser   239   ) , anti-PI3K, antiphosphor-PI3K, anti-Akt, anti-phosphor-Akt, and anti-rabbit IgG-horseradish peroxidase conjugate (HRP), and lysis buffer were obtained from Cell Signaling (Beverly, MA., USA). Polyvinylidene difluoride (PVDF) membrane was from GE Healthcare (Piseataway, NJ., USA). Enhanced chemiluminesence solution (ECL) was from GE Healthcare (Chalfont St., Giles, Buckinghamshire, UK). Fibrinogen Alexa Fluor 488 conjugate was obtained from Invitrogen Molecular Probes (Eugene, OR., USA).
Preparation of CE-WIB801C and quantity of cordycepin
The preparation of CE-WIB801C was performed according to the method of our previous report (Lee et al., 2014b) . Culture-solution of Cordyceps militaris-hypha was concentrated with a rotary vacuum evaporator (Eyela N3000, Rikakikai Co. Ltd., Tokyo, Japan) at 60°C. The concentrate was extracted by extraction-shaker (Cosmos 660, Kyungseo Co. Ltd., Seoul, Korea) at 60°C two times with n-butanol, which was filtered two times using a filter paper (Advantec No.2). The filtrate was completely concentrated by an evaporator (Eyela N3000, Rikakikai Co. Ltd., Tokyo, Japan) under reduced pressure (40°C), and was lyophilized and stored at -20°C until used. The quantity of cordycepin in CE-WIB801C was determined with calibration curve of (authentic cordycepin : 50, 100, 200, and 400 mg/mL) by HPLC as described in our previous report (Lee et al., 2014b) .
Purification of cordycepin in CE-WIB801C with prep-HPLC
The purification of cordycepin from CE-WIB801C was performed according to the Lee method (Lee et al., 2014c) . The methanol (50%) extract from CE-WIB801C was dissolved with 50% methanol and then purified by prep-HPLC. An Agilent 1100 liquid chromatography system (Palo Alto, CA, USA), equipped with vacuum degasser, quaternary gradient pump, autosampler and DAD, connected to an Agilent ChemStation software. A Jupiter C18 column (250 mm×21.2 mm id, 5 mm) were used at a column temperature of 25°C. The mobile phase consisted of water (A) and methanol with 0.01M KH2PO4 (B) using the following program: 0-30 min, 15% B. The flow rate was at 25 mL/min and sample injection volume was 1.5 mL. The UV detection was operated at 254 nm. The purified cordycepin were freeze-dried using a freeze dryer (Clean-vac 24T, Biotron, Korea) to obtain powder, which were analyzed and calculated by analytic HPLC above condition. The cordycepin was dissolved in distilled water, and used to investigate the effects on platelet aggregation. In this study, the cordycepin from CE-WIB801C was called as W-cordycepin to differentiate from authentic cordycepin.
Preparation of washed human platelets
Human platelet-rich plasma (PRP) anti-coagulated with acid-citrate-dextrose solution (0.8% citric acid, 2.2% sodium citrate, 2.45% glucose) were obtained from Korean Red Cross Blood Center (Changwon, Korea). PRP was centrifuged for 10 min at 125×g to remove a little red blood cells, and was centrifuged for 10 min at 1,300×g to obtain the platelet pellets. The platelets were washed twice with washing buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.36 mM NaH2PO4, 5.5 mM glucose, and 1 mM EDTA, pH 6.5). The washed platelets were then resuspended in suspension buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 0.36 mM NaH2PO4, 0.49 mM MgCl2, 5.5 mM glucose, 0.25% gelatin, pH 6.9) to a final concentration of 5×10 8 /mL. All of the above procedures were carried out at 25°C to avoid platelet aggregation from any effect of low temperature. The Korea National Institute for Bioethics Policy Public Institutional Review Board (Seoul, Korea) approved these experiments (PIRB12-072).
Measurement of platelet aggregation
Washed platelets (10 8 /mL) were preincubated for 3 min at 37°C in the presence of 2 mM CaCl2 with or without substances (CE-WIB801C, authentic cordycepin, W-cordycepin, Western blot for analysis of VASP-, PI3K-, and Akt-phosphorylations Washed platelets (10 8 /mL) were preincubated with or without substances in the presence of 2 mM CaCl2 for 3 min and then stimulated with collagen (10 mg/mL) for 5 min at 37°C in an aggregometer (Chrono-Log, Corp., Havertown, PA., USA) at a constant stirring speed of 1,000 rpm. The reactions were terminated by adding an equal volume (250 mL) of lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM serine/threonine phosphatase inhibitor b-glycerophosphate, 1 mM ATPase, alkaline and acid phosphatase, and protein phosphotyrosine phosphatase inhibitor Na3VO4, 1 mg/mL serine and cysteine protease inhibitor leupeptin, and 1 mM serine protease and acetylcholinesterase inhibitor phenylmethanesulfonyl fluoride, pH 7.5). Platelet lysates containing the same protein (20 mg) were used for the analysis. Protein concentrations were measured using a bicinchoninic acid protein assay kit (Pierce Biotechnology, IL., USA). The effects of substances on VASP-, PI3K-, and Akt-phosphorylation were analyzed using Western blotting. A 6-8% SDS-PAGE was used for electrophoresis and a PVDF membrane was used for protein transfer from the gel. The dilutions for anti-VASP, anti-phosphor-VASP (Ser 157 ), antiphosphor-VASP (Ser 239 ), anti-PI3K, anti-phosphor-PI3K, antiAkt, anti-phosphor-Akt, and anti-rabbit IgG-HRP were 1:1000, 1:1000, 1:1000, 1:1000, 1:1000, 1:1000, 1:1000, and 1:10000, respectively. The membranes were visualized using ECL. The blots were analyzed using the Quantity One, Ver. 4.5 (BioRad, Hercules, CA., USA).
Determination of fibrinogen binding to aIIb/b 3
Washed platelets (10 8 /mL) were preincubated for 3 min at 37°C with or without substances in the presence of 2 mM CaCl2 and then stimulated with collagen (10 mg/mL) in the presence of Alexa Flour 488-human fibrinogen (30 mg/mL) for 5 min at 37°C. The reaction was stopped by the addition of 0.5% paraformaldehyde in phosphate-buffered saline, and the samples were placed in the dark. Alexa Fluor 488-fibrinogen binding to platelets was determined using flow cytometry (BD Biosciences, San Jose, CA., USA) and fibrinogen binding to aIIb/b3 was analyzed using cellQuest software.
Determination of ATP secretion
Washed platelets (10 8 /mL) were preincubated for 3 min at 37°C with or without substances in the presence of 2 mM CaCl2 and then stimulated with collagen (10 mg/mL) for 5 min at 37°C in an aggregometer (Chrono-Log, Corp., Havertown, PA., USA) at a constant stirring speed of 1,000 rpm. The reaction was terminated by the addition of ice-cold 2 mM EDTA, the samples were centrifuged, and supernatants were used for the assay of ATP secretion from dense body. ATP secretion was measured with a luminometer (BioTek Instruments, Winooski, VT., USA) using ATP assay kit.
Determination of serotonin secretion
Washed platelets (10 8 /mL) were preincubated for 3 min at 37°C with or without substances in the presence of 2 mM CaCl2 and then stimulated with collagen (10 mg/ml) for 5 min at 37°C in an aggregometer (Chrono-Log, Corp., Havertown, PA., USA) at a constant stirring speed of 1,000 rpm. The reaction was terminated by the addition of ice-cold 2 mM EDTA, the samples were centrifuged and supernatants were used for the assay of serotonin secretion. Serotonin secretion was measured with a Synergy HT Multi-Model Microplate Reader (BioTek Instruments, Winoosku, VT., USA) using serotonin ELISA kit (Labor Diagnostika Nord GmbH & CO., Nordhorn, Germany).
Statistical analysis
The experimental results are expressed as the mean ± S.E.M. accompanied by the number of observations. The data were assessed using an analysis of variance (ANOVA). If the analysis indicated significant differences between the group means, then each group was compared according to the Newman-Keuls method. p<0.05 was considered to be statistically significant.
RESULTS
Composition of cordycepin in CE-WIB801C
The quantity of cordycepin in WIB801C was about 8.2% (81.98 ± 1.37 mg/g-WIB801C (Lee et al., 2014b) . It is known that whole fruiting body myelia of Cordyceps militaris contains 0.16% of cordycepin, and whole fruiting body, stroma, and larva of Cordyceps sinensis does not contain cordycepin (Yue et al., 2008 ). Accordingly, the cordycepin level in WIB801C that we used in this study is very higher than those in whole fruiting body myelia of Cordyceps militaris, or in whole fruiting body, stroma, and larva of Cordyceps sinensis. Thus, WIB801C is named as cordycepin-enriched WIB801C (CE-WIB801C) in this report. The yield of cordycepin from CE-WIB801C with prep-HPLC was 80.7% (Lee et al., 2014c) .
Effects of CE-WIB801C on collagen-induced platelet aggregation
The concentration of collagen-induced maximal platelet aggregation was approximately 10 mg/mL (Lee et al., 2014a) . Therefore, collagen (10 mg/mL) was used as the platelet ago- www.biomolther.org nist in this study. The light transmission in response to various concentrations of CE-WIB801C (100, 200, 400 mg/mL) in intact platelet was 4.3 ± 0.6% (at 100 mg/mL of CE-WIB801C), 4.0 ± 0.0% (at 200 mg/mL of CE-WIB801C), and 4.3 ± 0.6 (at 400 mg/mL of CE-WIB801C), respectively, which were not significantly different from that (4.0 ± 1.0%) in resting platelets. These mean that CE-WIB801C alone did not affect on platelet aggregation as compared with that in intact platelets without CE-WIB801C. When washed platelet platelets (10 8 /mL) were activated with collagen (10 mg/mL) in the presence of 2mM CaCl2, the aggregation was increased to 78.1 ± 1.7% (Fig. 2) . However, various concentrations (100, 200, 400 mg/mL) of CE-WIB801C dose dependently inhibited collagen-induced platelet aggregation (Fig. 2) . . Lane 1, Intact platelets (base); Lane 2, Collagen (10 mg/mL); Lane 3, Collagen (10 mg/mL)+CE-WIB801C (200 mg/mL); Lane 4, Collagen (10 mg/mL)+CE-WIB801C (400 mg/mL); Lane 5, Collagen (10 mg/mL)+CE-WIB801C (400 mg/mL)+Rp-8-Br-cAMPS (250 mM); Lane 6, Collagen (10 mg/ mL)+pCPT-cAMP (1 mM); Lane 7, Collagen (10 mg/mL)+cordycepin (500 mM); Lane 8, Collagen (10 mg/mL)+cordycepin (500 mM)+Rp-8-BrcAMPS (250 mM). (D) Effect of CE-WIB801C and cordycepin on p-VASP (Ser 239 ). Lane 1, Intact platelets (base); Lane 2, Collagen (10 mg/ mL); Lane 3, Collagen (10 mg/mL)+CE-WIB801C (200 mg/mL); Lane 4, Collagen (10 mg/mL)+CE-WIB801C (400 mg/mL); Lane 5, Collagen (10 mg/mL)+CE-WIB801C (400 mg/mL)+Rp-8-Br-cGMPS (250 mM); Lane 6, Collagen (10 mg/mL)+8-Br-cGMP (1 mM); Lane 7, Collagen (10 mg/ mL)+cordycepin (500 mM); Lane 8, Collagen (10 mg/mL)+cordycepin (500 mM)+Rp-8-Br-cGMPS (250 mM). Western blotting was performed as described in "Materials and Methods." The data are expressed as the mean ± S.E.M. (n=3). **p<0.001 versus the collagen-stimulated platelets, † † p<0.001 versus the collagen-stimulated platelets in the presence of CE-WIB801C (400 mg/mL), ## p<0.001 versus the collagenstimulated platelets in the presence of cordycepin (500 mM). 
Effects of CE-WIB801C and cordycepin on VASP phosphorylation
Because 200 and 400 mg/mL of CE-WIB801C (Fig. 2) , and 500 mM cordycepin (Cho et al., 2007a) significantly inhibited collagen-induced platelet aggregation, we used 200 and 400 mg/mL of CE-WIB801C, and 500 mM cordycepin. CE-WIB801C alone (200, 400 mg/mL), and cordycepin alone (500 mM) ( (Fig. 3C lane 1) , which involves in feedback inhibition by collagen (Gambaryan et al., 2010) . Akinase activator pCPT-cAMP stimulated VASP phosphorylation, indicating VASP phosphorylation (Ser 157 ) is dependent on cAMP in collagen-induced platelet aggregation (Fig. 3C  lane 6 ). CE-WIB801C (400 mg/mL), and cordycepin (500 mM) also increased p-VASP (Ser 157 ) (Fig. 3C lane 4, 7) , and CE-WIB801C (400 mg/mL) increased to 78.1% the ratio of p-VASP (Ser 157 ) to VASP in collagen-induced platelet aggregation (Table 1). A-kinase inhibitor Rp-8-Br-cAMPS decreased to 23.0% CE-WIB801C-elevated p-VASP (Ser 157 ) (Fig. 3C lane 5 and Table 1 ). With regard to the p-VASP (Ser 239 ), G-kinase activator increased p-VASP (Ser 239 ) (Fig. 3D lane 6) . CE-WIB801C alone (200, 400 mg/mL), and cordycepin alone (500 mM) ( Fig.  3B lane 2, 3 , and 4) also potently increased p-VASP (Ser 239 ) as compared with that ( Fig. 3B lane 1) of intact platelets, control. However, CE-WIB801C (200, 400 mg/mL), and cordycepin (500 mM) did not almost increase the p-VASP (Ser 239 ) (Fig.  3D lane 3, 4 , and 7) as compared with that ( Fig. 3D lane 2) by collagen. G-kinase inhibitor Rp-8-Br-cGMPS did not change p-VASP (Ser 239 ) in the presence of CE-WIB801C (400 mg/mL) or cordycepin (500 mM) in collagen-induced platelet aggregation (Fig. 3D lane 5, 8) .
Effects of CE-WIB801C and cordycepin on fibrinogen binding to aIIb/b 3 Next, we investigated whether the VASP phosphorylation by CE-WIB801C involved in inhibition of fibrinogen binding to aIIb/b3. As shown in Fig. 4 , collagen activated fibrinogen binding to aIIb/b3 (Fig. 4A-b) , and increased the degree of fibrinogen binding to aIIb/b3 up to 77.2 ± 5.5% as compared with that (5.4 ± 0.2%) of intact platelets, basal (Table 1) . However, CE-WIB801C inhibited collagen-activated fibrinogen binding to aIIb/b3 (Fig. 4A-c, 4B ), and its inhibitory degree was 89.2% as compared with that (77.2 ± 5.5%) by collagen (Table 1) .
Cordycepin also potently inhibited collagen-activated fibrinogen binding to aIIb/b3 (Fig. 4A-d and 4B ). Because the inhibition of aIIb/b3 is resulted from cAMP/A-kinase-and cGMP/Gkinase-mediated VASP phosphorylation, and it is known that Data were from Fig. 3C, 3D , 5B.
www.biomolther.org cAMP-and cGMP-increasing compounds involve in inhibition of aIIb/b3 (Horstrup et al., 1994; Barragan et al., 2003) , we investigated whether the inhibition of fibrinogen binding to aIIb/b3 by CE-WIB801C was contributed to which kinase of Akinase and G-kinase. A-kinase activator pCPT-cAMP and Gkinase activator 8-Br-cGMP inhibited collagen-induced fibrinogen binding to aIIb/b3, respectively (Fig. 5A-e, f and Fig. 5B ). It was confirmed that cAMP/A-kinase and cGMP/G-kinase pathway involve in inhibition of fibrinogen binding to aIIb/b3 in collagen-induced platelet aggregation. CE-WIB801C-inhibited fibrinogen binding to aIIb/b3 (Fig. 4A-c and Fig. 4B ) was elevated by A-kinase inhibitor Rp-8-Br-cAMPS (Fig. 5A-a and 
Fig
. 5B), and its stimulatory degree was 386.7% as compared with that (8.3%) by both CE-WIB801C and collagen (Table 1) . However, CE-WIB801C-inhibited fibrinogen binding to aIIb/b3 (Fig. 4A-c and Fig. 4B ) was not almost elevated by G-kinase inhibitor Rp-8-Br-cGMPS (Fig. 5A-b and Fig. 5B ), and its stimulatory degree was 6.0% as compared with that (8.3%) by both CE-WIB801C and collagen (Table 1) .
Effects of CE-WIB801C on PI3K/Akt phosphorylation
As apposed to the phosphorylated VASP, PI3K/Akt phosphorylation stimulates aIIb/b3 activation and fibrinogen binding (Zhang et al., 1996; Chen et al., 2004) . Thus, we investigated 
cAMPS), or G-kinase inhibitor (Rp-8-Br-cGMPS). (A)
The flow cytometry histograms on fibrinogen binding. a, Collagen (10 mg/mL)+CE-WIB801C (400 mg/mL)+Rp-8-Br-cAMPS (250 mM); b, Collagen (10 mg/mL)+CE-WIB801C (400 mg/mL)+Rp-8-Br-cGMPS (250 mM); c, Collagen (10 mg/mL)+cordycepin (500 mM)+Rp-8-Br-cAMPS (250 mM); d, Collagen (10 mg/mL)+cordycepin (500 mM)+ Rp-8-Br-cGMPS (250 mM); e, Collagen (10 mg/mL)+pCPT-cAMP (1 mM); f, Collagen (10 mg/mL)+8-Br-cGMP (1 mM). (B) Effects of CE-WIB801C and cordycepin on collagen-induced fibrinogen binding (%) in the presence of A-kinase inhibitor (Rp-8-Br-cAMPS) or G-kinase inhibitor . Determination of fibrinogen binding to aIIb/b 3 was carried out as described in "Materials and Methods." The data are expressed as the mean ± S.E.M. (n=4). **p<0.001 versus the collagen-stimulated platelets, † † p<0.001 ver sus the collagen-stimulated platelets in the presence of CE-WIB801C (400 mg/mL). the effect of CE-WIB801C, and cordycepin on phosphorylation of PI3K and its downstream molecule Akt. CE-WIB801C alone (200, 400 mg/mL), and cordycepin alone (500 mM) almost did not change p-PI3K (Fig. 6A lane 2, 3 , and 4) as compared with that ( Fig. 6A lane 1) of intact platelets, control. PI3K inhibitor wortmannin suppressed collagen-induced PI3K phosphorylation ( Fig. 6B lane 5) . Collagen potently phosphorylated PI3K ( Fig. 6B lane 2) as compared with that ( Fig. 6B lane 1) of intact platelets, however, CE-WIB801C (Fig. 6B lane 3, 4) and cordycepin ( Fig. 6B lane 6 ) inhibited collagen-induced PI3K phosphorylation. CE-WIB801C alone (200, 400 mg/mL), and cordycepin alone (500 mM) almost did not change p-Akt ( Fig.  6C lane 2, 3 , and 4) as compared with that ( Fig. 6C lane 1) of intact platelets, control. Collagen elevated the phosphorylation of PI3K target molecule Akt (Fig. 6D lane 2) , however, CE-WIB801C (Fig. 6D lane 3, 4) and cordycepin ( Fig. 6D lane  5) inhibited collagen-induced Akt phosphorylation.
Effects of CE-WIB801C on ATP and serotonin release
Collagen, ADP, and thrombin that activate aIIb/b3 release ATP and serotonin out of dense bodies to aggregate platelets, which due to the [Ca 2+ ]i mobilization by fibrinogen binding to aIIb/b3 (Weiss et al., 1974; Michal and Motamed, 1976; Kamruzzaman et al., 2013) . Because CE-WIB801C also inhibited [Ca 2+ ]i mobilization (Lee et al., 2014b) , and fibrinogen binding to aIIb/b3 (Fig. 4A-c) , we investigated whether CE-WIB801C, and cordycepin have inhibitory effect on collagen-elevated ATP and serotonin release. As shown in Fig. 7A , collagen re- phosphorylation in intact platelets. Lane 1, Intact platelets (base); Lane 2, CE-WIB801C (200 mg/mL); Lane 3, CE-WIB801C (400 mg/mL); Lane 4, Cordycepin (500 mM). (B) Effects of CE-WIB801C and cordycepin on PI3K phosphorylation. Lane 1, Intact platelets (base); Lane 2, Collagen (10 mg/mL); Lane 3, Collagen (10 mg/mL)+CE-WIB801C (200 mg/mL); Lane 4, Collagen (10 mg/mL)+CE-WIB801C (400 mg/ mL); Lane 5, Collagen (10 mg/mL)+Wortmannin (10 mM); Lane 6, Collagen (10 mg/mL)+Cordycepin (500 mM). (C) Effects of CE-WIB801C and cordycepin on Akt phosphorylation in intact platelets. Lane 1, Intact platelets (base); Lane 2, CE-WIB801C (200 mg/mL); Lane 3, CE-WIB801C (400 mg/mL); Lane 4, Cordycepin (500 mM). (D) Effects of CE-WIB801C and cordycepin on Akt phosphorylation. Lane 1, intact platelets (base); Lane 2, collagen (10 mg/mL); Lane 3, collagen (10 mg/mL)+CE-WIB801C (200 mg/mL); Lane 4, collagen (10 mg/mL)+CE-WIB801C (400 mg/mL); Lane 5, Collagen (10 mg/mL)+cordycepin (500 mM). The data are expressed as the mean ± S.E.M. (n=3). a p<0.05 versus non-stimulated platelets, *p<0.05, **p<0.001 versus the collagen-stimulated platelets.
www.biomolther.org leased to 3.91 ± 0.24 mM ATP from platelets, it's the stimulatory degree was 4,244% as compared with that (0.09 ± 0.02 mM) in intact platelets, control (Fig. 7A) . However, CE-WIB801C, and cordycepin potently inhibited ATP release by collagen (Fig. 7A) .
With regard to serotonin release, as shown in Fig. 7B , collagen potently released serotonin to 84.7 ± 6.5 ng/10 8 platelets, and its stimulatory degree was 636.5% as compared with that (11.5 ± 1.6 ng/10 8 platelets) in intact platelets, control (Fig.  7B) . However, CE-WIB801C, and cordycepin inhibited collagen-elevated serotonin release (Fig. 7B) .
Effects of cordycepin, W-cordycepin on collagen-induced platelet aggregation
CE-WIB801C (100, 200, 400 mg/mL) dose dependently inhibited collagen-induced platelet aggregation (Fig. 2) . To investigate whether cordycepin (W-cordycepin) of CE-WIB801C involved in inhibition of collagen-induced platelet aggregation by CE-WIB801C, we purified cordycepin from CE-WIB801C with prep-HPLC (Lee et al., 2014c) . The concentration of cordycepin (Mw. 251.14) was 81.98 ± 1.37 mg/g-CE-WIB801C (8.2%) (Lee et al., 2014b) . The concentration of CE-WIB801C that inhibited collagen-induced platelet aggregation was at least 100, 200, 400 mg/mL (Fig. 2, Lee et al., 2014b) . In this study, therefore, to investigate the synergistic effect of cordycepin, or W-cordycepin with CE-WIB801C on collagen-induced platelet aggregation, we used 33, 66, 132 mM of cordycepin, or Wcordycepin corresponding to cordycepin concentration that contains in CE-WIB801C (100, 200, 400 mg/mL). As the results, as shown in Fig. 8A and 8C, the light transmissions (4.3 ± 0.6~5.0 ± 1.0%) in response to various concentration (33, 66, 132 μM) of cordycepin, and W-cordycepin alone was not significantly different from that (4.0 ± 1.0%) in resting platelets. However, cordycepin and W-cordycepin inhibited collagen-induced platelet aggregation in a dose (33, 66, 132 mM) dependent manner. With regard to the synergistic effect of cordycepin or W-cordycepin with CE-WIB801C on collagen-induced platelet aggregation. As shown in Fig. 8B and 8D , when platelets were activated by collagen in the presence of both CE-WIB801C (200 mg/mL) and cordycepin (33, 66, 132 mM) (Fig. 8B) or Wcordycepin (33, 66, 132 mM) (Fig. 8D) , the aggregation was dose dependently decreased as compared with that (42.1 ± 2.4%) by CE-WIB801C (200 mg/mL) alone. The aggregation (21.5 ± 1.8%) by both cordycepin (132 mM) and CE-WIB801C (200 mg/mL) was lower as compared with that (42.1 ± 2.4%) by CE-WIB801C (200 mg/mL) alone in collagen-induced platelet aggregation. In addition, the aggregation (14.4 ± 2.7%) by both W-cordycepin (132 mM) and CE-WIB801C (200 mg/mL) was lower as compared with that (42.1 ± 2.4%) by CE-WIB801C (200 mg/mL) alone in collagen-induced platelet aggregation. Furthermore, the inhibitory degree of collagen-induced platelet aggregation by CE-WIB801C together with cordycepin or W-cordycepin was also increased in a dose dependent manner. Therefore, it is thought that cordycepin or W-cordycepin with CE-WIB801C have a synergistic inhibitory effect on collagen-induced platelet aggregation, and the inhibition (Fig. 2) is resulted from antiplatelet function of W-cordycepin in CE-WIB801C.
DISCUSSION
A downstream pathway of both cAMP/A-kinase and cGMP/ G-kinase involves in VASP phosphorylation to inhibit fibrinogen binding to aIIb/b3. Ser 157 at 50 kDa of VASP is phosphorylated by the cAMP/A-kinase pathway, whereas Ser 239 at 50 kDa of VASP is phosphorylated by the cGMP/G-kinase pathway (Horstrup et al., 1994; Smolenski et al., 1998) . CE-WIB801C and cordycepin phosphorylated A-kinase substrate VASP (Ser 157 ) in intact platelets, and collagen-activated platelets. It is unknown whether CE-WIB801C increases cAMP level in intact platelets. Cordycepin (500 mM) increased cAMP level about 100 fmol/10 9 platelets in intact platelets (Cho et al., 2007a) . We could not explain how the cAMP level (100 fmol/10 9 platelets) that was increased by cordycepin (500 mM) involved in VASP (Ser 157 ) phosphorylation in intact platelets. However, this phenomenon could be explained from the report (Eigenthaler et al., 1992 ) that a very small elevation in cAMP is enough to activate most A-kinase. CE-WIB801C elevated cAMP level to 18.1 ± 1.0 pmol/10 9 platelets (Lee et al., 2014b) , and cordycepin (500 mM) increased cAMP level to 7.5 pmol/10 9 platelets in collagen-induced platelet aggregation (Cho et al., 2007a) . Therefore, it is thought that CE-WIB801C and cordycepin increase the level of cAMP, and subsequently involve in VASP (Ser 157 ) phosphorylation via A-kinase activation in collagen-induced platelet aggregation. If not so, CE-WIB801C-, and cordycepin-induced VASP (Ser 157 ) phosphorylation would not be inhibited by A-kinase inhibitor Rp- 8-Br-cAMPS in collagen-induced platelet aggregation. With regard to VASP (Ser 239 ) phosphorylation, CE-WIB801C and cordycepin phosphorylated G-kinase substrate VASP (Ser 239 ) in intact platelets, but did not phosphorylate that in collageninduced platelet aggregation. Unfortunately, we could not explain the different phenomena of VASP (Ser 239 ) phosphorylation caused by CE-WIB801C and cordycepin in intact platelets and collagen-activated platelets, which are necessary to study in the future. It is known that A-kinase plays predominately in the cGMP-phosphorylated VASP to inhibit platelet aggregation (Li et al., 2003) , which reflects that CE-WIB801C-, and cordycepin-indcued VASP (Ser 157 ) phosphorylation was inhibited by A-kinase inhibitor Rp-8-Br-cAMPS, and was dependent on cAMP/A-kinase pathway.
A-kinase inhibitor Rp-8-Br-cAMPS increased CE-WIB801C-, and cordycepin-inhibited fibrinogen binding to aIIb/b3. This means that CE-WIB801C and cordycepin inhibit fibrinogen binding to aIIb/b3 via cAMP/A-kinase pathway. In this report, we have established that the inhibitory effect by CE-WIB801C and cordycepin on collagen-induced aIIb/b3 activation is due to cAMP/A-kinase-dependent VASP (Ser 157 ) phosphorylation. It is known that the phosphorylation of PI3K and Akt involves in aIIb/b3 activation, an index of fibrinogen binding to aIIb/b3, in collagen-, ADP-, thrombin-induced platelet activation (Morello et al., 2009) . cAMP-elevating agents (i.e. cilostamide, cilostazole, and forskolin) are known to inhibit PI3K-and Akt-phosphorylation in collagen-induced platelet aggregation (Hayashi and Sudo, 2009 ) and cAMP/A-kinase pathway is known to involve in suppression of aIIb/b3 activation (van Willigen and Akkerman, 1991; Payrastre et al., 2000; Shattil and Newman, 2004) . Our findings show that CE-WIB801C (Lee et al., 2014b) , and cordycepin (Cho et al., 2007a) increases cAMP and subsequently stimulates the phosphorylation of VASP (Ser 157 ), on the contrary, inhibits the phosphorylation of both PI3K and Akt to inhibit fibrinogen binding to aIIb/b3 on collagen-induced platelet aggregation.
A lot of agonists such as collagen, thrombin and ADP mobilize [Ca 2+ ]i to phosphorylate Ca 2+ /calmodulin-dependent myosin light chain (20 kDa), which involves in granule secretion such as ATP and serotonin (Nishikawa et al., 1980; Kaibuchi et al., 1982) .
The inhibition of ATP and serotonin secretion by CE-WIB801C and cordycepin is associated with the elevation of cAMP level and the inhibition of [Ca 2+ ]i mobilization, which www.biomolther.org also supports the facts that CE-WIB801C induced the cAMPdependent phosphorylation of IP3R to inhibit [Ca 2+ ]i mobilization (Lee et al., 2014b) . In our another study, we observed that cordycepin inhibits [Ca 2+ ]i mobilization by phosphorylating IP3R in collagen-induced platelet aggretion (Data not shown). In addition, inhibition of 20kDa phosphorylation by cordycepin (Cho et al., 2006; 2007a) might be resulted in inhibition of ATP and serotonin release by cordycepin.
The purified W-cordycepin from CE-WIB801C, and cordycepin inhibited collagen-induced platelet aggregation. In addition, because W-cordycepin, and cordycepin had a synergistic inhibitory effect with CE-WIB801C on collagen-induced platelet aggregation, it is thought that the inhibition of collagen-induced platelet aggregation by CE-WIB801C might be resulted from the inhibitory effect by at least W-cordycepin. If so, this reflects the possibility that W-cordycepin in CE-WIB801C would directly or indirectly involve in phosphorylation of VASP (Ser 157 ), and dephosphorylation of PI3K and Akt to inhibit fibrinogen binding to aIIb/b3.
Platelet aggregation is generated at site of vascular wall injury, and is involved in the formation of thrombus. During the formation of thrombus, platelets release cell growth proteins such as platelet-derived growthfactor (PDGF), and vascular endothelial growth factor (VEGF) (Holash et al., 1999; Castro-Malaspina et al., 1981) . It is well established that PDGF and VEGF induce the proliferation of fibroblast, vascular smooth cells, and epithelial cells, and subsequently enhance the rate of atherosclerosis lesion progression (Seppä et al., 1982; Schwartz and Ross, 1984; Packham and Mustad, 1986; Schwartz and Reidy, 1987; Nagai et al., 2005) . The progression of atherosclerosis is strongly induced by inflammatory cell such as monocyte/macrophage, and neutrophil (Philips et al., 2005) . Although CE-WIB801C and cordycepin have antiplatelet effects, if CE-WIB801C and cordycepin do not inhibit inflammation by leukocyte, the progression of atherosclerosis lesion would be generated at site of vascular wall injury, and a question for antiplatelet effects of CE-WIB801C or cordycepin might be raised. Kim et al. (2006) reported that cordycepin inhibits lipopolysaccharide-induced inflammation by inhibiting Akt phosphorylation and NF-κB activity. In addition, cordycepin is known to inhibit protein synthesis by attenuating Akt/mTOR signaling pathway in NIH3T3 fibroblast, which means that cordycepin has an inhibitory effect on proliferation of NIH3T3 fibroblast (Wong et al., 2010) . Considering our results and these two previous reports that cordycepin inhibits platelet aggregation, inflammation, and fibroblast proliferation, it is thought that CE-WIB801C, and cordycepin may have antithrombotic-, and antiatherosclerotic-effects without inflammation and progression of atherosclerotic lesion at site of vascular wall injury. Therefore, CE-WIB801C and cordycepin is highlighted as an non-toxic antiplatelet compound.
Antiplatelet drugs such as thienopyridine derivatives (i.e. ticlopidine, clopidogrel) have characteristics that phosphorylate VASP, inhibit [Ca 2+ ]i mobilization, and inhibit aIIb/b3 activation, which is mediated by cAMP or cGMP (Barragan et al., 2003) . Therefore, it is thought that CE-WIB801C and cordycepin as well as thienopyridine derivatives may also represent a useful tool in the therapy and prevention of vascular diseases associated with platelet aggregation.
